Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Avillion opens IND for phase II study of Merck KGaA's M-1095

Feb. 19, 2018

Pfizer's PF-04965842 granted FDA breakthrough therapy designation for atopic dermatitis

Feb. 15, 2018

Sienna announces first patient dosed in phase I/II study of SNA-125 for psoriasis

Feb. 15, 2018

FDA grants priority review to Rituxan sBLA in pemphigus vulgaris

Feb. 14, 2018

Treatment begins in phase II SHINE-1 study of scar reduction with EB-001

Feb. 9, 2018

Lifesci Pharmaceuticals discloses new plasma kallikrein inhibitors

Feb. 7, 2018

Dermira begins phase IIb study of lebrikizumab in moderate to severe atopic dermatitis

Feb. 1, 2018

Leo Pharma divulges RORG ligands for psoriasis

Jan. 30, 2018

FDA awards RMAT designation to Abeona Therapeutics' EB-101

Jan. 30, 2018

First patient treated in phase II study of Novan's SB-206 for molluscum contagiosum

Jan. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...